RxDoctor Payments Data

Brandy Farmer

Family · Rock Hill, SCNPI 1184998742

Payments from drug & device makers

$6,551in general payments, 2019–2025

Across 302 payments — averaging $21.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$775
  • Abbott$759
  • Mannkind Corporation$454
  • Novo Nordisk$395
  • Corcept Therapeutics$359
  • Amgen$349
  • plus $3K from 39 others

What the payments were for

  • Food & beverage$6,551100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,551 in reported general payments places this provider in the 95th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$2,137
Medicare patients
19
Services billed
41

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide104$156,816
TrulicityDulaglutide65$121,918
MounjaroTirzepatide86$114,800
FarxigaDapagliflozin Propanediol54$65,781
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog49$38,585
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/719$25,702
JardianceEmpagliflozin15$20,978
Fiasp FlextouchInsulin Aspart (Niacinamide)13$16,174
Tresiba Flextouch U-100Insulin Degludec22$15,060
KerendiaFinerenone16$13,705
Humulin R U-500 KwikpenInsulin Regular, Human12$12,715
Humalog Kwikpen U-100Insulin Lispro37$8,934
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$8,539
Novolog FlexpenInsulin Aspart29$8,429
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$6,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$775$242,025190 claims
Novo NordiskOzempic$395$156,816104 claims
AstraZenecaFarxiga$35$65,78154 claims
Boehringer IngelheimJardiance$223$20,97815 claims
BayerKerendia$222$13,70516 claims
IBSA Pharma Inc.Tirosint-Sol$169$3,65423 claims
AbbVieSynthroid, Armour Thyroid$140$2,21437 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$22$1,606141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,248 family providers in South Carolina.

Other family in Rock Hill

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →